# Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer

> **NCT06919159** · — · COMPLETED · sponsor: **Jiequn Yu** · enrollment: 45 (actual)

## Conditions studied

- Prostate Cancer (Diagnosis)
- Prostate-specific Membrane Antigen
- Positron Emission Tomography (PET)

## Interventions

- **DIAGNOSTIC_TEST:** PSMA PET/CT scan
- **DIAGNOSTIC_TEST:** FDG-PET

## Key facts

- **NCT ID:** NCT06919159
- **Lead sponsor:** Jiequn Yu
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2022-11-20
- **Final completion:** 2022-11-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06919159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06919159, "Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06919159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*